Importance of Regular Examination and Follow-up in Pediatric Patients with Neurogenic Bladder: 24-Month Follow-up Study Using a Japanese Health Insurance Database

[1] Shan S(2022)Video-urodynamics efficacy of sacral neuromodulation for neurogenic bladder guided by three-dimensional imaging CT and C-arm fluoroscopy: a single-center prospective study Sci Rep 12 16306-1289

[2] Zhu W(2019)Drug utilization patterns and healthcare resource use and costs in patients with neurogenic bladder in the United Kingdom: a retrospective primary care database study Neurourol Urodyn 38 1278-401

[3] Zhang G(2011)Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database Neurourol Urodyn 30 395-489

[4] Jaggi A(2020)Urologic guidelines for the care and management of people with spina bifida J Pediatr Rehabil Med 13 479-478

[5] Nazir J(2017)Pharmacotherapy for pediatric neurogenic bladder Paediatr Drugs 19 463-127

[6] Fatoye F(2023)Diagnosis and treatment of Japanese children with neurogenic bladder: analysis of data from a national health insurance database J Clin Med 12 3191-274

[7] Manack A(2021)Data resource profile: JMDC claims database sourced from health insurance societies J Gen Fam Med 22 118-57

[8] Motsko SP(2022)A multinational survey on the management of the urinary tract in newborns with spina bifida: are we following current EAU/ESPU guidelines? Neurourol Urodyn 41 264-506

[9] Haag-Molkenteller C(2020)EAU/ESPU guidelines on the management of neurogenic bladder in children and adolescent part I diagnostics and conservative treatment Neurourol Urodyn 39 45-229

[10] Joseph DB(2020)EAU/ESPU guidelines on the management of neurogenic bladder in children and adolescent part II operative management Neurourol Urodyn 39 498-536

[1] Shan S(2022)Video-urodynamics efficacy of sacral neuromodulation for neurogenic bladder guided by three-dimensional imaging CT and C-arm fluoroscopy: a single-center prospective study Sci Rep 12 16306-1289

[2] Zhu W(2019)Drug utilization patterns and healthcare resource use and costs in patients with neurogenic bladder in the United Kingdom: a retrospective primary care database study Neurourol Urodyn 38 1278-401

[3] Zhang G(2011)Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database Neurourol Urodyn 30 395-489

[4] Jaggi A(2020)Urologic guidelines for the care and management of people with spina bifida J Pediatr Rehabil Med 13 479-478

[5] Nazir J(2017)Pharmacotherapy for pediatric neurogenic bladder Paediatr Drugs 19 463-127

[6] Fatoye F(2023)Diagnosis and treatment of Japanese children with neurogenic bladder: analysis of data from a national health insurance database J Clin Med 12 3191-274

[7] Manack A(2021)Data resource profile: JMDC claims database sourced from health insurance societies J Gen Fam Med 22 118-57

[8] Motsko SP(2022)A multinational survey on the management of the urinary tract in newborns with spina bifida: are we following current EAU/ESPU guidelines? Neurourol Urodyn 41 264-506

[9] Haag-Molkenteller C(2020)EAU/ESPU guidelines on the management of neurogenic bladder in children and adolescent part I diagnostics and conservative treatment Neurourol Urodyn 39 45-229

[10] Joseph DB(2020)EAU/ESPU guidelines on the management of neurogenic bladder in children and adolescent part II operative management Neurourol Urodyn 39 498-536